应用<sup>99</sup>Tc<sup>m</sup>-MIBI纳米粒子SPECT-CT显像评价乳腺癌对新辅助化疗的耐药性试验研究初探

李卫鹏; 李辉; 胡永全; 陶新全; 申勇; 孙景秋; 袁超

doi:10.16766/j.cnki.issn.1674-4152.003498

应用⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像评价乳腺癌对新辅助化疗的耐药性试验研究初探

doi: 10.16766/j.cnki.issn.1674-4152.003498

蚌埠医科大学第一附属医院核医学科，安徽蚌埠 233004

基金项目:

安徽省高校自然科学研究重点项目 2023AH052016

蚌埠医学院自然科学基金重点项目 2020byzd097

详细信息

通讯作者:
袁超，E-mail：ychsysu@163.com

中图分类号: R737.9 R-332
计量
- 文章访问数: 121
- HTML全文浏览量: 81
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-11

Preliminary study of SPECT-CT imaging with ⁹⁹Tc^m-MIBI nanoparticles in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy

Department of Nuclear Medicine, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

摘要

摘要: 目的初步探讨应用⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像在评价乳腺癌对新辅助化疗的耐药性试验中的价值，旨在寻找一种预测新辅助化疗疗效的无创评价手段。方法制备⁹⁹Tc^m-MIBI纳米粒子显像剂；构建荷人乳腺癌裸鼠的模型；对裸鼠模型采用表柔比星联合多西他赛(ET)化疗：第1、2天表柔比星40 mg/(m²·d)，尾静脉给药；第3天多西他赛60 mg/m²，尾静脉给药，3周为1个周期，共化疗3个周期；化疗前后应用⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像，观察影像变化情况，通过ROI技术，计算每只乳腺癌裸鼠模型的肿瘤与周围本底的比值(T/B)。结果根据UICC实体瘤疗效评定标准进行评估人乳腺癌裸鼠的模型联合化疗后的疗效，在40只人乳腺癌裸鼠模型中，部分缓解(PR)27只，疾病稳定(SD)12只，疾病进展(PD)1只；人乳腺癌裸鼠模型化疗前行⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像的T/B为2.98±0.73，部分缓解组(PR)裸鼠模型化疗后行⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像的T/B为1.52±0.59，T/B值与化疗前比较差异有统计学意义(P<0.05)；疾病稳定(SD)组裸鼠模型化疗后行⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像的T/B为3.12±1.09，与化疗前差异无统计学意义(P>0.05)。结论对于乳腺癌患者，有望采用⁹⁹Tc^m-MIBI纳米粒子SPECT-CT显像来评价对新辅助化疗药物的治疗效果，这是一种无创的评价乳腺癌对新辅助化疗耐药性的方法。
- ⁹⁹Tc^m-MIBI /
- SPECT-CT显像 /
- 乳腺癌 /
- 新辅助化疗
Abstract: Objective To explore the value of SPECT-CT imaging with ⁹⁹Tc^m-MIBI nanoparticle in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy, to find a non-invasive evaluation method to predict the efficacy of neoadjuvant chemotherapy. Methods The imaging agent ⁹⁹Tc^m-MIBI nanoparticle was prepared and the nude mouse model of carcinoma of breast was established. The nude mouse model was treated with combination chemotherapy of epirubicin and docetaxel (ET) as follows: on the 1st day, epirubicin 40 mg/(m·d) was administered via tail vein for two days, then on the 3rd day, docetaxel 60 mg/m² was administered via tail vein, 3 weeks per cycle, with a total of 3 cycles of chemotherapy. ⁹⁹Tc^m-MIBI nanoparticles SPECT-CT imaging was used before and after chemotherapy to observe the image changes. The ratio of tumor to surrounding background (T/B) of each nude mouse model of breast cancer was calculated by ROI technology. Results According to UICC solid tumor efficacy evaluation criteria, the efficacy of combined chemotherapy in nude mice with human breast cancer was evaluated, In 40 nude mouse models of human breast cancer, 27 partial remission (PR), 12 disease stability (SD), and 1 disease progression (PD); The T/B of ⁹⁹Tc^m-MIBI nanoparticles SPECT-CT imaging before chemotherapy in nude mouse model of human breast cancer was 2.98±0.73, The T/B value of ⁹⁹Tc^m-MIBI nanoparticle SPECT-CT imaging after chemotherapy in the partially relieved (PR) nude mouse model was 1.52±0.59, and there was a significant difference in T/B value compared to before chemotherapy (P<0.05); The T/B of ⁹⁹Tc^m-MIBI nanoparticle SPECT-CT imaging in the disease stable (SD) nude mouse model after chemotherapy was 3.12±1.09, and the difference was not significant compared to before chemotherapy (P>0.05). Conclusion For breast cancer patients, ⁹⁹Tc^m-MIBI nanoparticles SPECT-CT imaging is expected to evaluate the therapeutic effect of neoadjuvant chemotherapy drugs, which is a non-invasive method to evaluate the drug resistance of breast cancer to neoadjuvant chemotherapy.
- ⁹⁹Tc^m-MIBI /
- SPECT-CT imaging /
- Breast cancer /
- Neoadjuvant chemotherapy
利益冲突 无

HTML全文

图 1 荷瘤鼠SPECT-CT静态显像

注：A、B、C分别为化疗前、PR以及SD的2.0 h显像。

Figure 1. Static SPECT-CT imaging of tumor-bearing mice

下载: 全尺寸图片幻灯片

表 1 新辅助化疗前后⁹⁹Tc^m-MIBI纳米粒子摄取变化与化疗效果的关系

Table 1. Relationship between changes in ⁹⁹Tc^m-MIBI nanoparticle uptake and chemotherapy efficacy before and after neoadjuvant chemotherapy

组别	例数	化疗前	化疗后	t值	P值
部分缓解	27	2.98±0.73	1.52±0.59	3.952	0.018
疾病稳定	12	2.97±0.76	3.12±1.09	1.536	0.135
统计量		0.342^a	4.241^b
P值		0.735	0.012
注：^a为t值，^b为F值。

下载: 导出CSV

参考文献(15)

[1]	TERUYA N, INOUE H, HORⅡ R, et al. Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer[J]. Cancer Med, 2023, 12(9): 10526-10535. doi: 10.1002/cam4.5788
[2]	AKAMINE Y, YASUI-FURUKORI N, UNO T. Drug-drug interactions of P-gp substrates unrelated to CYP metabolism[J]. Curr Drug Metab, 2019, 20(2): 124-129. doi: 10.2174/1389200219666181003142036
[3]	WEI X, SONG M, LI W, et al. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance[J]. Theranostics, 2021, 11(13): 6334-6354. doi: 10.7150/thno.59342
[4]	GOMES C M, ABRUNHOSA A J, PAUWELS E K, et al. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [⁹⁹Tc^m] sestamibi and [⁹⁹Tc^m] tetrofosmin[J]. Cancer Biother Radiopharm, 2009, 24(2): 215-217.
[5]	BURAK Z, MORETTI J L, ERSOY O, et al. ^99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression[J]. J Nucl Med, 2003, 44(9): 1394-1401.
[6]	DUAN X Y, WANG J S, LIU M, et al. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer[J]. Ann Nucl Med, 2008, 22(1): 49-55. doi: 10.1007/s12149-007-0080-5
[7]	袁超, 张勇, 焦举, 等. 载雄激素受体三螺旋形成寡核苷酸PEG-PLGA纳米粒子的制备与应用[J]. 中山大学学报(医学科学版), 2008, 29(5): 602-605. doi: 10.3321/j.issn:1672-3554.2008.05.022 YUAN C, ZHANG Y, JIAO J, et al. Preparation and application of PEG-PLGA nanoparticles loaded with androgen receptor triple helix forming oligonucleotides[J]. Journal of Sun Yat Sen University (Medical Science Edition), 2008, 29(5): 602-605. doi: 10.3321/j.issn:1672-3554.2008.05.022
[8]	BELHAJ-TAYEB H, BRIANE D, VERGOTE J, et al. In vitro and in vivo study of ^99mTc-MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumour imaging[J]. Eur J Nucl Med Mol Imaging, 2003, 30(4): 502-509. doi: 10.1007/s00259-002-1038-4
[9]	袁超, 李辉, 申勇, 等. ⁹⁹Tc^m-MIBI脂质体纳米粒制备及生物分布实验研究[J]. 中华全科医学, 2018, 16(50): 721-724. doi: 10.16766/j.cnki.issn.1674-4152.000196 YUAN C, LI H, SHEN Y, et al. Preparation of ⁹⁹Tc^m-MIBI liposome nanoparticles and experimental study on their biological distribution[J]. Chinese Journal of General Practice, 2018, 16(50): 721-724. doi: 10.16766/j.cnki.issn.1674-4152.000196
[10]	LOPES-RODRIGUES V, DI LUAC A, SOUSA D, et al. Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells[J]. Data Brief, 2016, 6(3): 1023-1027.
[11]	MA J, ZHAO Z, WU K, et al. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC[J]. Gene, 2016, 587(2): 147-154. doi: 10.1016/j.gene.2016.04.054
[12]	ALEXIOU G A, XOURGIA X, VARTHOLOMATOS E, et al. Comparison of ^99mTc-tetrofosmin and ^99mTc-sestamibi uptake in glioma cell lines: the role of p-glycoprotein expression[J]. Int J Mol Imaging, 2014, 2014: 471032. DOI. org/10.1155/2014/471032.
[13]	YANG T J, AUKEMA T S, VAN TINTEREN H, et al. Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer[J]. Mol Imaging Biol, 2010, 12(2): 174-180. doi: 10.1007/s11307-009-0250-z
[14]	陆智祥, 江勇, 余大富, 等. 非霍奇金淋巴瘤化疗后⁹⁹Tc^m-MIBI显像的价值[J]. 实用医学杂志, 2015, 31(22): 3732-3735. doi: 10.3969/j.issn.1006-5725.2015.22.032 LU Z X, JIANG Y, YU D F, et al. The value of ⁹⁹Tc^m-MIBI imaging in non Hodgkin ' s lymphoma after chemotherapy[J]. Journal of Practical Medicine, 2015, 31(22): 3732-3735. doi: 10.3969/j.issn.1006-5725.2015.22.032
[15]	江生, 黄志顺, 肖国有. ⁹⁹Tc^m-MIBI乳腺亲肿瘤显像对乳腺癌的诊断价值分析[J]. 中国医学装备, 2021, 18(1): 63-67. doi: 10.3969/J.ISSN.1672-8270.2021.01.016 JIANG S, HUANG Z S, XIAO G Y. Analysis of the diagnostic value of ⁹⁹Tc^m-MIBI breast tumor imaging for breast cancer[J]. Chinese Medical Equipment, 2021, 18(1): 63-67. doi: 10.3969/J.ISSN.1672-8270.2021.01.016